173 related articles for article (PubMed ID: 18341668)
61. Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity.
Zwaveling J; Bredius RG; Cremers SC; Ball LM; Lankester AC; Teepe-Twiss IM; Egeler RM; den Hartigh J; Vossen JM
Bone Marrow Transplant; 2005 Jan; 35(1):17-23. PubMed ID: 15502853
[TBL] [Abstract][Full Text] [Related]
62. Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology.
Hassan M; Oberg G; Bekassy AN; Aschan J; Ehrsson H; Ljungman P; Lönnerholm G; Smedmyr B; Taube A; Wallin I
Cancer Chemother Pharmacol; 1991; 28(2):130-4. PubMed ID: 2060084
[TBL] [Abstract][Full Text] [Related]
63. Influence of GST polymorphisms on busulfan pharmacokinetics in Japanese children.
Nishikawa T; Yamaguchi H; Ikawa K; Nakayama K; Higashi E; Miyahara E; Abematsu T; Nakagawa S; Kodama Y; Tanabe T; Shigemi A; Shinkoda Y; Okamoto Y; Takeda Y; Kawano Y
Pediatr Int; 2019 Jun; 61(6):558-565. PubMed ID: 30963629
[TBL] [Abstract][Full Text] [Related]
64. Population pharmacokinetics of treosulfan and development of a limited sampling strategy in children prior to hematopoietic stem cell transplantation.
Danielak D; Twardosz J; Kasprzyk A; Wachowiak J; Kałwak K; Główka F
Eur J Clin Pharmacol; 2018 Jan; 74(1):79-89. PubMed ID: 28975382
[TBL] [Abstract][Full Text] [Related]
65. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation.
Ansari M; Théoret Y; Rezgui MA; Peters C; Mezziani S; Desjean C; Vachon MF; Champagne MA; Duval M; Krajinovic M; Bittencourt H;
Ther Drug Monit; 2014 Feb; 36(1):93-9. PubMed ID: 24061446
[TBL] [Abstract][Full Text] [Related]
66. A simple approximation for busulfan dose adjustment in adult patients undergoing bone marrow transplantation.
Hoffer E; Akria L; Tabak A; Scherb I; Rowe JM; Krivoy N
Ther Drug Monit; 2004 Jun; 26(3):331-5. PubMed ID: 15167637
[TBL] [Abstract][Full Text] [Related]
67. A Nonparametric Method to Optimize Initial Drug Dosing and Attainment of a Target Exposure Interval: Concepts and Application to Busulfan in Pediatrics.
Philippe M; Neely M; Bertrand Y; Bleyzac N; Goutelle S
Clin Pharmacokinet; 2017 Apr; 56(4):435-447. PubMed ID: 27585476
[TBL] [Abstract][Full Text] [Related]
68. Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter?
Clemmons AB; Evans S; DeRemer DL; Awan FT
J Oncol Pharm Pract; 2015 Dec; 21(6):425-32. PubMed ID: 24986792
[TBL] [Abstract][Full Text] [Related]
69. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics.
Hassan M; Oberg G; Björkholm M; Wallin I; Lindgren M
Cancer Chemother Pharmacol; 1993; 33(3):181-6. PubMed ID: 8269597
[TBL] [Abstract][Full Text] [Related]
70. Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia.
Baker KS; Bostrom B; DeFor T; Ramsay NK; Woods WG; Blazar BR
Bone Marrow Transplant; 2000 Sep; 26(6):607-14. PubMed ID: 11041565
[TBL] [Abstract][Full Text] [Related]
71. Trough level monitoring of intravenous busulfan to estimate the area under the plasma drug concentration-time curve in pediatric hematopoietic stem cell transplant recipients.
Watanabe E; Nishikawa T; Ikawa K; Yamaguchi H; Abematsu T; Nakagawa S; Kurauchi K; Kodama Y; Tanabe T; Shinkoda Y; Matsumoto K; Okamoto Y; Takeda Y; Kawano Y
Int J Hematol; 2015 Nov; 102(5):611-6. PubMed ID: 26243625
[TBL] [Abstract][Full Text] [Related]
72. Weight-based strategy of dose administration in children using intravenous busulfan: clinical and pharmacokinetic results.
Michel G; Valteau-Couanet D; Gentet JC; Esperou H; Socié G; Méchinaud F; Doz F; Neven B; Bertrand Y; Galambrun C; Demeocq F; Yakouben K; Bordigoni P; Frappaz D; Nguyen L; Vassal G
Pediatr Blood Cancer; 2012 Jan; 58(1):90-7. PubMed ID: 21254374
[TBL] [Abstract][Full Text] [Related]
73. Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients.
Sam WJ; Aw M; Quak SH; Lim SM; Charles BG; Chan SY; Ho PC
Br J Clin Pharmacol; 2000 Dec; 50(6):531-41. PubMed ID: 11136292
[TBL] [Abstract][Full Text] [Related]
74. Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients.
Zwaveling J; Press RR; Bredius RG; van Derstraaten TR; den Hartigh J; Bartelink IH; Boelens JJ; Guchelaar HJ
Ther Drug Monit; 2008 Aug; 30(4):504-10. PubMed ID: 18641537
[TBL] [Abstract][Full Text] [Related]
75. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule.
Madden T; de Lima M; Thapar N; Nguyen J; Roberson S; Couriel D; Pierre B; Shpall EJ; Jones RB; Champlin RE; Andersson BS
Biol Blood Marrow Transplant; 2007 Jan; 13(1):56-64. PubMed ID: 17222753
[TBL] [Abstract][Full Text] [Related]
76. Pharmacokinetics of temozolomide given three times a day in pediatric and adult patients.
Riccardi A; Mazzarella G; Cefalo G; Garrè ML; Massimino M; Barone C; Sandri A; Ridola V; Ruggiero A; Mastrangelo S; Lazzareschi I; Caldarelli M; Maira G; Madon E; Riccardi R
Cancer Chemother Pharmacol; 2003 Dec; 52(6):459-64. PubMed ID: 13680160
[TBL] [Abstract][Full Text] [Related]
77. Accurately Achieving Target Busulfan Exposure in Children and Adolescents With Very Limited Sampling and the BestDose Software.
Neely M; Philippe M; Rushing T; Fu X; van Guilder M; Bayard D; Schumitzky A; Bleyzac N; Goutelle S
Ther Drug Monit; 2016 Jun; 38(3):332-42. PubMed ID: 26829600
[TBL] [Abstract][Full Text] [Related]
78. Pharmacokinetics and distribution of liposomal busulfan in the rat: a new formulation for intravenous administration.
Hassan M; Hassan Z; Nilsson C; Rehim MA; Kumlien S; Elfsson B; Kållberg N
Cancer Chemother Pharmacol; 1998; 42(6):471-8. PubMed ID: 9788573
[TBL] [Abstract][Full Text] [Related]
79. Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram.
Rhee SJ; Lee JW; Yu KS; Hong KT; Choi JY; Hong CR; Park KD; Shin HY; Song SH; Kang HJ; Lee H
Am J Hematol; 2017 Jul; 92(7):607-613. PubMed ID: 28370238
[TBL] [Abstract][Full Text] [Related]
80. Clinical pharmacokinetics of carboplatin in children.
Riccardi R; Riccardi A; Lasorella A; Di Rocco C; Carelli G; Tornesello A; Servidei T; Iavarone A; Mastrangelo R
Cancer Chemother Pharmacol; 1994; 33(6):477-83. PubMed ID: 8137457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
